The investor presentation “MagSense® Technology: Early Detection of Cancer Through Targeted Imaging” has been announced and is available for download here.
Download the non-deal roadshow presentation MagSense Technology.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer